Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

Share :
Published: 29 Sep 2012
Views: 3723
Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain

Data presented at a press conference during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna Dr Luis Paz-Ares explained that treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC).